Erectile Dysfunction: Serious Research for a Serious Problem

You have probably heard more than your share of Viagra jokes; a whole Web site is devoted to them. But impotence, or erectile dysfunction (ED), is no joke. According to a survey (H.A. Feldman et al., Journal of Urology, 151:54-61, 1994), more than 50 percent of men between 40 and 70 suffer from some degree of ED. The figure climbs to 67 percent at age 70. That's 20 to 30 million men, according to the National Institutes of Health. FIRST IN LINE: Viagra is actually the second drug approved t

| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

You have probably heard more than your share of Viagra jokes; a whole Web site is devoted to them. But impotence, or erectile dysfunction (ED), is no joke. According to a survey (H.A. Feldman et al., Journal of Urology, 151:54-61, 1994), more than 50 percent of men between 40 and 70 suffer from some degree of ED. The figure climbs to 67 percent at age 70. That's 20 to 30 million men, according to the National Institutes of Health.

By the end of the second quarter of 1998, Viagra sales accounted for more than $400 million of the company's $1 billion increase in total revenues compared to 1997. And by mid-August, 30 million pills had been dispensed. These figures reflect mainly domestic sales--38 other countries have now approved Viagra, including the 15 nations of the European Union, with 41 more expected by year's end. Financial analysts project a worldwide market ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Barry Palevitz

    This person does not yet have a bio.
  • Ricki Lewis

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo